Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set of new highs for the S&P 500 and the Nasdaq, as AI fever overshadowed Iran's peace counteroffer dis
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e
Insulet (PODD) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.02 per share a year ago.
Insulet raised its annual revenue growth forecast on Wednesday after reporting better-than-expected quarterly results, ​driven by strong demand for its tubeless ‌insulin pumps that eliminate the n

Insulet Reports First Quarter 2026 Results

07:00am, Wednesday, 06'th May 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

Insulet (PODD) Upgraded to Buy: Here's Why

01:01pm, Monday, 04'th May 2026
Insulet (PODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes.
On April 30, 2026, Insulet Corp (PODD) shares rose 7.6% today, bringing the current price to $172.14. However, the stock has faced significant volatility, with
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Insulet (PODD). But which of these two stocks presents investors with the bet
The U.S. Food and Drug Administration (FDA) has classified a recall of Insulet Corporation's (NASDAQ:PODD) Omnipod 5 Pods as its most serious type, warning that continued use of affected devices could
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will pres
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE